CoChat

Glycoengineering of pertuzumab and its impact on the pharmacokinetic/pharmacodynamic properties

Open access
Luo, Cheng, Chen, Song, Xu, Na, Wang, Chi, Sai, Wen bo, Zhao, Wei, Li, Ying chun, Hu, Xiao jing, Tian, Hong, Gao, Xiang dong, Yao, Wen bing · 2017 · Scientific Reports
Cited by 41

The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.

Abstract

Pertuzumab is an antihuman HER2 antibody developed for HER2 positive breast cancer. Glycosylation profiles are always the important issue for antibody based therapy. Previous findings have suggested the impact of glycosylation profiles on the function of antibodies, like pharmacodynamics, antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). However, the roles of fucose and sialic acid in the function of therapeutic antibodies still need further investigation, especially the role of sialic acid in nonfucosylated antibodies. This study focused on the pharmacokinetic and pharmacodynamic properties of pertuzumab after glycoengineering. Herein, nonfucosylated pertuzumab was produced in CHOFUT8−/− cells, and desialylated pertuzumab was generated by enzymatic hydrolysis. Present data indicated that fucose was critical for ADCC activity by influencing the interaction between pertuzumab and FcγRIIIa, nevertheless removal of sialic acid increased the ADCC and CDC activity of pertuzumab. Meanwhile, regarding to sialic acid, sialidase hydrolysis directly resulted in asialoglycoprotein receptors (ASGPRs) dependent clearance in hepatic cells in vitro. The pharmacokinetic assay revealed that co-injection of asialofetuin can protect desialylated pertuzumab against ASGPRs-mediated clearance. Taken together, the present study elucidated the importance of fucose and sialic acid for pertuzumab, and also provided further understanding of the relationship of glycosylation/pharmacokinetics/pharmacodynamics of therapeutic antibody.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/srep46347

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 14 references

Cited by

See all 41

Metadata

Authors
Luo, C., Chen, S., Xu, N., Wang, C., Sai, W. B., Zhao, W., Li, Y. C., Hu, X. J., Tian, H., Gao, X. D., & Yao, W. B.
Venue
Scientific Reports
Published
2017-04-11
Volume
7
Issue
1
Pages
46347-46347
ISSN
2045-2322 (ISSN-L)
OpenAlex
W2605404264
Cited by
41
References
14
FWCI
3.41
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Glycoengineering of pertuzumab and its impact on the pharmacokinetic/pharmacodynamic properties. https://app.cochat.ai/papers/10.1038/srep46347
The paper
Luo, C., Chen, S., Xu, N., Wang, C., Sai, W. B., Zhao, W., Li, Y. C., Hu, X. J., Tian, H., Gao, X. D., & Yao, W. B. (2017). Glycoengineering of pertuzumab and its impact on the pharmacokinetic/pharmacodynamic properties. Scientific Reports. https://doi.org/10.1038/srep46347

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.